Alnylam Pharmaceuticals Ownership | Who Owns Alnylam Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Alnylam Pharmaceuticals Ownership Summary


Alnylam Pharmaceuticals is owned by 95.06% institutional investors, 0.42% insiders, and 4.52% retail investors. Capital world investors is the largest institutional shareholder, holding 11.87% of ALNY shares. Capital Group Growth Fnd of Amer Comp is the top mutual fund, with 8.45% of its assets in Alnylam Pharmaceuticals shares.

ALNY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAlnylam Pharmaceuticals95.06%0.42%4.52%
SectorHealthcare Stocks 47.31%8.01%44.69%
IndustryBiotech Stocks 45.43%7.81%46.75%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Capital world investors14.97M11.87%$3.64B
Vanguard group12.51M9.92%$3.04B
Fmr12.16M9.64%$2.96B
Blackrock9.55M7.57%$2.32B
Wellington management group llp6.21M4.92%$1.51B
Baillie gifford6.03M4.78%$1.47B
Capital investors3.89M3.08%$945.65M
Dodge & cox3.78M3.00%$918.58M
State street3.53M2.80%$858.97M
Price t rowe associates inc /md/3.49M2.77%$847.59M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bridger management37.02K4.63%$9.00M
Bellevue group919.83K3.63%$223.52M
Eagle health investments lp76.26K3.25%$18.53M
Casdin capital170.00K3.15%$41.31M
Rosenblum silverman sutton s f inc /ca35.20K2.29%$8.55M
683 capital management122.90K2.26%$29.86M
Antipodes partners238.75K2.16%$59.43M
Silverarc capital management36.00K2.06%$8.75M
Rhenman & partners asset management ab85.50K1.99%$20.78M
Artia global partners lp35.00K1.64%$8.51M

Top Buyers

HolderShares% AssetsChange
Norges bank2.30M0.08%2.30M
Fmr12.16M0.19%2.20M
Capital world investors14.97M0.59%2.18M
Orbis allan gray721.05K1.09%721.05K
Blackrock9.55M0.05%522.66K

Top Sellers

HolderShares% AssetsChange
Wellington management group llp6.21M0.27%-998.53K
Baillie gifford6.03M1.14%-590.92K
Logos global management lp---500.00K
Deep track capital, lp---500.00K
Avoro capital advisors---400.00K

New Positions

HolderShares% AssetsChangeValue
Norges bank2.30M0.08%2.30M$558.12M
Orbis allan gray721.05K1.09%721.05K$175.22M
Adage capital partners gp254.00K0.11%254.00K$61.72M
Frontier capital management168.44K0.41%168.44K$40.93M
Bank of america corp /de/83.50K0.00%83.50K$20.29M

Sold Out

HolderChange
Johnson financial group-1.00
Financial gravity asset management-1.00
Harbor investment advisory-1.00
Cva family office-3.00
Abound wealth management-3.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20245713.25%119,905,1276.57%951.19%2864.38%1623.18%
Mar 31, 20245533.56%112,509,382-3.80%891.02%2743.40%1571.95%
Dec 31, 20235348.32%116,949,4790.55%931.09%26528.02%154-7.23%
Sep 30, 20234930.20%116,310,429-1.58%921.03%207-2.82%1667.10%
Jun 30, 2023492-1.01%118,178,469-1.00%941.02%213-6.58%155-7.74%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Capital Group Growth Fnd of Amer Comp10.84M8.45%1.60M
American Funds Growth Fund of Amer A10.84M8.45%1.60M
Vanguard Total Stock Mkt Idx Inv4.06M3.14%-15.03K
Vanguard Health Care Inv4.02M3.12%-1.01M
Capital Group New Perspective Comp3.71M2.89%245.21K
American Funds New Perspective A3.71M2.89%245.21K
Capital Group AMCAP Composite3.07M2.39%443.45K
VA CollegeAmerica Amcap 529A3.07M2.39%443.45K
Vanguard Mid Cap Index Institutional2.72M2.11%4.91K
Dodge & Cox Stock I2.32M1.80%-29.10K

Recent Insider Transactions


DateNameRoleActivityValue
Aug 20, 2024Greenstreet Yvonne Chief Executive OfficerSell$4.20M
Aug 12, 2024Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$2.61M
Aug 12, 2024Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$1.56M
Aug 12, 2024Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$1.07M
Aug 12, 2024Fitzgerald Kevin Joseph CSO & EVP, Head of ResearchSell$381.77K

Insider Transactions Trends


DateBuySell
2024 Q4--
2024 Q3-16
2024 Q2-67
2024 Q1-46
2023 Q4-1

ALNY Ownership FAQ


Who Owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals shareholders are primarily institutional investors at 95.06%, followed by 0.42% insiders and 4.52% retail investors. The average institutional ownership in Alnylam Pharmaceuticals's industry, Biotech Stocks , is 45.43%, which Alnylam Pharmaceuticals exceeds.

Who owns the most shares of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s largest shareholders are Capital world investors (14.97M shares, 11.87%), Vanguard group (12.51M shares, 9.92%), and Fmr (12.16M shares, 9.64%). Together, they hold 31.43% of Alnylam Pharmaceuticals’s total shares outstanding.

Does Blackrock own Alnylam Pharmaceuticals?

Yes, BlackRock owns 7.57% of Alnylam Pharmaceuticals, totaling 9.55M shares as of Jun 2024. This represents 0.05% of BlackRock's total assets, with a market value of 2.32B$. In the last quarter, BlackRock increased its holdings by 522.66K shares, a 5.79% change.

Who is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Bridger management is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 4.63% of its assets in 37.02K Alnylam Pharmaceuticals shares, valued at 9M$.

Who is the top mutual fund holder of Alnylam Pharmaceuticals shares?

Capital Group Growth Fnd of Amer Comp is the top mutual fund holder of Alnylam Pharmaceuticals shares, with 8.45% of its total shares outstanding invested in 10.84M Alnylam Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools